Bone marrow morphology during haematopoietic stem cell mobilisation with cyclophosphamide in mice

The aim of the study was to examine the morphology of the bone marrow of mice after stimulation with cyclophosphamide (Cy). The experimental mice were given a single intraperitoneal injection with 250 mg/kg bw cyclophosphamide. After 2, 4 and 6 days of experiment the femurs were obtained for morphological study. On the 2nd day after the mobilisation of the mice with Cy destruction of the bone marrow was observed with a decrease in the haematopoietic compartment and an increase in the area occupied by sinusoids filled with erythrocytes. Erythrocytes were located among the haematopoietic cells, which indicated that the endothelial barrier had been disrupted. On the 4th day after treating the mice with Cy, repair processes in the bone marrow were conducted, including macrophages. The cells filled with haemosiderin migrated from the extravascular compartment of the bone marrow into the lumen of the sinusoids. There were proliferating cells among the haematopoietic cells. On the 6th day the morphology of the bone marrow was similar to the morphology of that in the control mice. However, more haematopoietic cells were visible compared to the control bone marrow. The presence of an increased number of leucocytes in the sinusoid lumen in comparison with the control suggested that at that time the migration of haematopoietic cells from the bone marrow had been initiated

Diagnostyka histopatologiczna guzów ośrodkowego układu nerwowego

W opracowaniu diagnostycznym guzów ośrodkowego układu nerwowego (OUN) kluczowe znaczenie ma dokonanie właściwego rozpoznania neuropatologicznego. Decyduje ono o formie terapii, a ponadto określa rokowanie dotyczące przeżycia chorego. W pracy przedstawiono znaczenie najważniejszych metod służących do rozpoznawania guzów: klasycznej, w której wykorzystuje się barwienie hematoksyliną i eozyną, immunohistochemicznych, z użyciem mikroskopii elektronowej oraz biologii molekularnej, zwracając jednocześnie uwagę na wciąż podstawowe znaczenie metody klasycznej. Podkreślono, że metody immunohistochemiczne, choć nieodzowne, należy traktować jako komplementarne wobec metody podstawowej. Wskazano na zalety i wady metod śródoperacyjnych (cytopatologicznej i opartej na materiale mrożonym) oraz parafinowych, a także na najważniejsze przyczyny trudności w diagnostyce neuropatologicznej guzów OUN. Trudności te wynikają z wadliwego pobrania materiału (spoza nowotworu, zbyt mała ilość, uszkodzenie fizyczne), złego utrwalenia materiału, jego nieprawidłowego transportu, złego opracowania laboratoryjnego, a także z powodów obiektywnych - bardzo dużej heterogenności nowotworów OUN i zbyt małego doświadczenia osoby oceniającej. Podkreślono znaczenie danych klinicznych, w tym wyników badań neuroobrazowych i wyglądu śródoperacyjnego guza, którymi powinien dysponować neuropatolog, zanim postawi ostateczną diagnozę. Przeanalizowano algorytm postępowania diagnostycznego, którym neuropatolog powinien się posługiwać, by uniknąć pochopnych decyzji

Izolowany przerzut raka jasnokomórkowego do splotu naczyniówkowego

Chora w wieku 60 lat, obciążona nadciśnieniem tętniczym, dyslipidemią i otyłością, przebyła nefrektomię lewostronną z powodu jasnokomórkowego raka nerki. Sześć miesięcy później, nagle, doszło do porażenia połowiczego lewostronnego. Na podstawie tomografii komputerowej rozpoznano krwotok śródmózgowy z przebiciem do układu komorowego. Badanie to nie dostarczyło informacji na temat guza. Po kolejnych 5 miesiącach u chorej wystąpiły bóle głowy i zaburzenia świadomości. Tomografia komputerowa mózgowia uwidoczniła rozległy krwiak śródmózgowy zlokalizowany w wieńcu promienistym prawej półkuli mózgu, z efektem masy. Po wykonaniu tomografii rezonansu magnetycznego, ze względu na podejrzenie krwawienia do guza, pacjentkę poddano zbiegowi neurochirurgicznemu przy użyciu techniki neuronawigacji. Na podstawie badania histopatologicznego rozpoznano przerzut raka jasnokomórkowego nerki do splotu naczyniówkowego prawej komory bocznej

Morphology of the bone marrow, spleen and liver during hematopoietic cell mobilization with cyclophosphamide in mice.

Cyclophosphamide (CY), the agent with cytoreductive activity, is widely exploited in cancer chemotherapy, and can be used alone or in combination with various cytokines and growth factors to stimulate the egress of hematopoietic stem/progenitor cells (HSPC) from the BM compartment. The aim of the present study was to exam the morphology and ultrastructure of the bone marrow, spleen and liver of mice injected intraperitoneally with a single dose of cyclophosphamide (200 mg/kg bw) and the localization of cells expressing markers of early hematopoietic cells in studied organs and the peripheral blood. We observed that the CY-induced morphological changes in the BM and spleen were reconstructed on day 4. of experiment, and the spleen was repopulated by HSPC on the 6th day. In this time, the highest number of c-Kit-R-positive cells was determined by flow cytometry in the peripheral blood. The results confirmed, that the egress of HSPC from the bone marrow into the peripheral blood was delayed compared to mice treated with G-CSF or GCS-F plus CY

JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Treatment-Naïve Patients

Multiple sclerosis (MS) treatment with new agents is associated with the risk of the development of progressive multifocal leukoencephalopathy (PML). The seropositivity and a high index of anti-John Cunningham virus (JCV) antibodies are some of the risk factors for PML development. The aim of this study was to assess the seroprevalence of anti-JCVAb and JCVAb index (AI), as well as its correlations with demographic and clinical characteristics in treatment-naïve Polish MS patients. This is a multicenter, prospective, and cross-sectional study involving 665 MS patients. The overall prevalence of anti-JCVAb was 65.3%, while 63.1% of seropositive patients had an index level of >1.5. The seroprevalence was shown to increase along with the patient’s age. Except for age, the prevalence of anti-JCVAb was not associated with demographic or clinical data. No correlations between the index levels and the demographic or clinical data were observed. In Poland, the seroprevalence of anti-JCVAb in treatment-naïve MS patients is one of the highest in Europe. The majority of seropositive patients had an anti-JCV antibody level denoting a high-risk category. This means that we need further studies to be conducted on the individualization of MS treatment in order to provide patients with an appropriate therapeutic safety level

JC Virus Seroprevalence and JCVAb Index in Polish Multiple Sclerosis Patients Treated with Immunomodulating or Immunosuppressive Therapies

The use of a highly-effective treatment for multiple sclerosis (MS) is associated with a severe risk of developing complications, such as progressive multifocal leukoencephalopathy (PML) caused by the John Cunningham virus (JCV). The aim of this study was to evaluate the correlation between anti-JCV Ab seroprevalence, anti-JCV AI, demographic and clinical factors as well as the type of therapy used in the Polish MS population. This is a multicentre, prospective and cross-sectional study involving 1405 MS patients. The seroprevalence of anti-JCV Ab and anti-JCV AI levels as well as AI categories were analysed with the use of a second-generation two-step ELISA test (STRATIFY JCV DxSelect). The overall prevalence of anti-JCV Ab was 65.8%. It was shown that seroprevalence increases with the patient’s age. The seroprevalence was significantly associated with the treatment type, and the highest values (76%) were obtained from immunosuppressant-treated patients. Overall, 63.3% of seropositive patients had an antibody index (AI) level of >1.5. In the seropositive patient group, the mean AI level amounted to 2.09. Similarly to the seroprevalence, AI levels correlated with the patient’s age; AI level for patients above 40 years old and from subsequent age quintiles plateaued, amounting to at least 1.55. Patients treated with immunosuppressants and immunomodulatory drugs obtained the highest (1.67) and lowest (1.35) AI levels, respectively. Of the immunosuppressants used, the highest mean AI levels were observed in mitoxantrone and cladribine groups, amounting to 1.75 and 1.69, respectively. In patients treated with immunomodulatory drugs, the lowest AI levels were observed in the dimethyl fumarate (DMF) group (1.11). The seroprevalence rate in the Polish MS population is one of the highest in Europe. The majority of seropositive patients had an anti-JCV Ab level qualifying them for a high-risk category. The highest mean AI levels are observed in patients receiving immunosuppressants, especially mitoxantrone and cladribine. Patients receiving immunomodulatory drugs have lower AI levels compared to treatment-naïve subjects, especially when treated with DMF. Further studies, especially longitudinal studies, are required to determine the impact of MS drugs on the seroprevalence of anti-JCV Ab and AI levels

Modified Rio score with platform therapy predicts treatment success with fingolimod and natalizumab in relapsing-remitting multiple sclerosis patients

Background: Reliable markers of disease outcomes in multiple sclerosis (MS) would help to predict the response to treatment in patients treated with high efficacy drugs. No evidence of disease activity (NEDA) has become a treatment goal whereas the modified Rio score (MRS) predicts future suboptimal responders to treatment. The aim of our study was to identify factors that would predict poor response to treatment with natalizumab and fingolimod. Methods: In the multicenter prospective trial, 336 subjects were enrolled, initiating therapy with natalizumab (n = 135) or fingolimod (n = 201). Data on relapse rate, the expanded disability status scale, and MRI results were collected, and MRS was estimated. Results: NEDA-3 after the first year of therapy was 73.9% for natalizumab and 54.8% for fingolimod (p < 0.0001). Patients with MRS = 0 in the last year on platform therapy had the best NEDA-3 (71%) and patients with MRS = 3 had the worst NEDA-3 (41%) in the first year of treatment with the second-line therapy. Conclusion: We conclude that switching to the second-line therapy should occur earlier to enable better results for patients treated with natalizumab or fingolimod. The outcome on both drugs is better with better neurological conditions and lower MRS of the patient on the platform therapy

Into Peripheral Blood in Patients After Stroke Clinical Evidence That Very Small Embryonic-Like Stem Cells Are Mobilized Clinical Evidence That Very Small Embryonic-Like Stem Cells Are Mobilized Into Peripheral Blood in Patients After Stroke

Background and Purpose-In a murine model of stroke, we identified a population of very small embryonic-like (VSEL) stem cells (SCs) in adult murine bone marrow that could be mobilized into peripheral blood (PB). This raised the question of whether a similar population of cells is mobilized in human stroke patients. Methods-We evaluated a number of cells that corresponded to VSEL SCs in the PB of 44 stroke patients and 22 age-matched controls. After each patient's stroke, PB samples were harvested during the first 24 hours, on day ϩ3, and on day ϩ7 and then compared with normal controls. The circulating human cells with the phenotype of VSEL SCs were evaluated in PB by real-time quantitative polymerase chain reaction, fluorescence-activated cell sorting analysis, and direct immunofluorescence staining. In parallel, we also measured the serum concentration of stromal derived factor-1 by ELISA. Results-In stroke patients, we found an increase in the number of circulating cells expressing SC-associated antigens, such as CD133, CD34, and CXCR4. More important, we found an increase in the number of circulating primitive cells expressing the VSEL phenotype (CXCR